Opus Point Partners Management as of March 31, 2015
Portfolio Holdings for Opus Point Partners Management
Opus Point Partners Management holds 65 positions in its portfolio as reported in the March 2015 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Receptos | 3.5 | $4.2M | 26k | 164.88 | |
| Salix Pharmaceuticals | 3.5 | $4.1M | 24k | 172.79 | |
| Clovis Oncology | 3.5 | $4.2M | 56k | 74.23 | |
| BioMarin Pharmaceutical (BMRN) | 3.4 | $4.1M | 33k | 124.63 | |
| Incyte Corporation (INCY) | 3.4 | $4.0M | 44k | 91.66 | |
| Medivation | 3.3 | $4.0M | 31k | 129.09 | |
| Regeneron Pharmaceuticals (REGN) | 3.3 | $4.0M | 8.8k | 451.43 | |
| Biogen Idec (BIIB) | 3.3 | $3.9M | 9.3k | 422.25 | |
| Seattle Genetics | 3.3 | $3.9M | 111k | 35.35 | |
| Alnylam Pharmaceuticals (ALNY) | 3.3 | $3.9M | 37k | 104.42 | |
| ISIS Pharmaceuticals | 3.2 | $3.9M | 61k | 63.67 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 3.2 | $3.9M | 33k | 117.97 | |
| Celgene Corporation | 3.2 | $3.8M | 33k | 115.29 | |
| Illumina (ILMN) | 3.2 | $3.8M | 21k | 185.65 | |
| Alexion Pharmaceuticals | 3.2 | $3.8M | 22k | 173.30 | |
| Alkermes (ALKS) | 3.2 | $3.8M | 63k | 60.96 | |
| Nektar Therapeutics (NKTR) | 3.1 | $3.7M | 336k | 11.00 | |
| Pharmacyclics | 2.9 | $3.5M | 14k | 255.96 | |
| Cepheid | 2.6 | $3.1M | 55k | 56.90 | |
| Mettler-Toledo International (MTD) | 2.6 | $3.1M | 9.4k | 328.64 | |
| Pacira Pharmaceuticals (PCRX) | 2.6 | $3.1M | 35k | 88.84 | |
| Bio-techne Corporation (TECH) | 2.6 | $3.1M | 31k | 100.30 | |
| Qiagen | 2.6 | $3.1M | 123k | 25.20 | |
| Proshares Tr pshs ult nasb (BIB) | 2.4 | $2.8M | 18k | 158.40 | |
| Synageva Biopharma | 1.4 | $1.7M | 18k | 97.51 | |
| Hologic (HOLX) | 1.4 | $1.7M | 50k | 33.02 | |
| Array BioPharma | 1.2 | $1.5M | 200k | 7.37 | |
| Esperion Therapeutics (ESPR) | 1.2 | $1.4M | 15k | 92.60 | |
| Vericel (VCEL) | 1.1 | $1.3M | 362k | 3.70 | |
| Tesaro | 1.0 | $1.1M | 20k | 57.40 | |
| D Stemline Therapeutics | 0.9 | $1.1M | 75k | 14.47 | |
| XenoPort | 0.8 | $926k | 130k | 7.12 | |
| Momenta Pharmaceuticals | 0.8 | $912k | 60k | 15.20 | |
| Epizyme | 0.8 | $908k | 48k | 18.78 | |
| United Therapeutics Corporation (UTHR) | 0.8 | $899k | 5.2k | 172.45 | |
| Merrimack Pharmaceuticals In | 0.7 | $855k | 72k | 11.87 | |
| Ocera Therapeutics | 0.7 | $860k | 183k | 4.71 | |
| Assembly Biosciences | 0.7 | $861k | 65k | 13.25 | |
| Tenax Therapeutics | 0.7 | $812k | 249k | 3.26 | |
| Celladon | 0.7 | $803k | 42k | 18.93 | |
| Amgen (AMGN) | 0.7 | $789k | 4.9k | 159.78 | |
| Flamel Technologies | 0.6 | $751k | 42k | 17.97 | |
| Ultragenyx Pharmaceutical (RARE) | 0.6 | $745k | 12k | 62.08 | |
| Chimerix (CMRX) | 0.6 | $722k | 19k | 37.70 | |
| Bluebird Bio (BLUE) | 0.6 | $725k | 6.0k | 120.83 | |
| Mirati Therapeutics | 0.6 | $733k | 25k | 29.32 | |
| Xencor (XNCR) | 0.6 | $685k | 45k | 15.33 | |
| Achillion Pharmaceuticals | 0.6 | $658k | 67k | 9.86 | |
| Relypsa | 0.5 | $649k | 18k | 36.06 | |
| Aerie Pharmaceuticals | 0.5 | $627k | 20k | 31.35 | |
| Repros Therapeutics Inc *w exp 02/04/201 | 0.5 | $597k | 98k | 6.09 | |
| Arrowhead Research | 0.5 | $556k | 82k | 6.77 | |
| Agios Pharmaceuticals (AGIO) | 0.4 | $472k | 5.0k | 94.40 | |
| Macrogenics (MGNX) | 0.4 | $471k | 15k | 31.40 | |
| Karyopharm Therapeutics (KPTI) | 0.4 | $459k | 15k | 30.60 | |
| Omeros Corporation (OMER) | 0.4 | $441k | 20k | 22.05 | |
| Otonomy | 0.4 | $424k | 12k | 35.33 | |
| Zogenix | 0.3 | $411k | 300k | 1.37 | |
| Avalanche Biotechnologies In | 0.3 | $405k | 10k | 40.50 | |
| Acelrx Pharmaceuticals | 0.3 | $386k | 100k | 3.86 | |
| Kalobios Pharmaceuticals | 0.3 | $366k | 747k | 0.49 | |
| Gilead Sciences (GILD) | 0.3 | $358k | 3.7k | 98.06 | |
| National Holdings | 0.3 | $349k | 90k | 3.90 | |
| Mei Pharma | 0.1 | $54k | 30k | 1.80 | |
| Neptune Technologies Bioreso | 0.0 | $1.0k | 36.00 | 27.78 |
